DuPont Decomposition

Why does INDRAMEDCO earn its ROE?

Breaking down Return on Equity into profitability, efficiency, and leverage.

ROE = Net Margin × Asset Turnover × Equity Multiplier

27.0% = 12.3% × 1.53 × 1.43

Latest: FY2025

Profitability

Net Margin

12.3%

7.8% →12.3%

How much profit per ₹ of revenue

Efficiency

Asset Turnover

1.53x

1.98x →1.53x

Revenue per ₹ of assets

Leverage

Equity Multiplier

1.43x

1.46x →1.43x

Assets funded by equity vs debt

Trend Analysis

ROE improved by 4.3 pp over 3 years. Driven by net margin improving (7.8% → 12.3%), asset turnover declining (1.98x → 1.53x).

Historical Decomposition

Last 3 years

YearRevenuePATNet MarginAsset TOLeverageROE
FY20230Cr0Cr7.8%1.981.4622.7%
FY20240Cr0Cr10.0%1.721.5125.9%
FY20250Cr0Cr12.3%1.531.4327.0%

How to read DuPont

  • Rising ROE from margin = pricing power, operational improvement (good)
  • Rising ROE from turnover = better asset utilization (good)
  • Rising ROE from leverage = more debt, amplified risk (caution)
  • Falling ROE across all three = structural deterioration (red flag)

See DCF fair value for INDRAMEDCO

Combine financial quality with intrinsic value.

See Fair Value →

DuPont decomposition from audited annual financials. Factual analysis, not investment advice.

INDRAMEDCO DuPont Analysis — ROE 27.0% | YieldIQ